{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T20:12:17Z","timestamp":1792613537979,"version":"4.5.0"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Stroke"],"published-print":{"date-parts":[[2011,3]]},"abstract":"<jats:sec>\n            <jats:title>Background and Purpose\u2014<\/jats:title>\n            <jats:p>Osteopontin (OPN) is neuroprotective in ischemic brain injuries in adult experimental models; therefore, we hypothesized that OPN would provide neuroprotection and improve long-term neurological function in the immature brain after hypoxic\u2013ischemic (HI) injury.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods\u2014<\/jats:title>\n            <jats:p>\n              HI was induced by unilateral ligation of the right carotid artery followed by hypoxia (8% O\n              <jats:sub>2<\/jats:sub>\n              for 2 hours) in postnatal Day 7 rats. OPN (0.03 \u03bcg or 0.1 \u03bcg) was injected intracerebroventricularly at 1 hour post-HI. Temporal expression of endogenous OPN was evaluated in the normal rat brain at the age of 0, 4, 7, 11, 14, and 21 days and in the ipsilateral hemisphere after HI. The effects of OPN were evaluated using 2-3-5-triphenyl tetrazolium chloride staining, apoptotic cell death assay, and cleaved caspase-3 expression. Neurological function was assessed by the Morris water maze test.\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results\u2014<\/jats:title>\n            <jats:p>Endogenous OPN expression in the brain was the highest at the age of 0 day with continuous reduction until the age of 21 days during development. After HI injury, endogenous OPN expression was increased and peaked at 48 hours. Exogenous OPN decreased infarct volume and improved neurological outcomes 7 weeks after HI injury. OPN-induced neuroprotection was blocked by an integrin antagonist.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions\u2014<\/jats:title>\n            <jats:p>OPN-induced neuroprotection was associated with cleaved-caspase-3 inhibition and antiapoptotic cell death. OPN treatment improved long-term neurological function against neonatal HI brain injury.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1161\/strokeaha.110.599118","type":"journal-article","created":{"date-parts":[[2011,1,28]],"date-time":"2011-01-28T04:44:59Z","timestamp":1296189899000},"page":"764-769","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":75,"title":["Osteopontin Reduced Hypoxia\u2013Ischemia Neonatal Brain Injury by Suppression of Apoptosis in a Rat Pup Model"],"prefix":"10.1161","volume":"42","author":[{"given":"Wanqiu","family":"Chen","sequence":"first","affiliation":[{"name":"From the Departments of Physiology and Pharmacology (W.C., Q.M., H.S., J.T., J.H.Z.), Psychology (R.H.), and Neurosurgery (J.H.Z.), Loma Linda University School of Medicine, School of Science and Technology, Loma Linda, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyi","family":"Ma","sequence":"additional","affiliation":[{"name":"From the Departments of Physiology and Pharmacology (W.C., Q.M., H.S., J.T., J.H.Z.), Psychology (R.H.), and Neurosurgery (J.H.Z.), Loma Linda University School of Medicine, School of Science and Technology, Loma Linda, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Suzuki","sequence":"additional","affiliation":[{"name":"From the Departments of Physiology and Pharmacology (W.C., Q.M., H.S., J.T., J.H.Z.), Psychology (R.H.), and Neurosurgery (J.H.Z.), Loma Linda University School of Medicine, School of Science and Technology, Loma Linda, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Hartman","sequence":"additional","affiliation":[{"name":"From the Departments of Physiology and Pharmacology (W.C., Q.M., H.S., J.T., J.H.Z.), Psychology (R.H.), and Neurosurgery (J.H.Z.), Loma Linda University School of Medicine, School of Science and Technology, Loma Linda, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiping","family":"Tang","sequence":"additional","affiliation":[{"name":"From the Departments of Physiology and Pharmacology (W.C., Q.M., H.S., J.T., J.H.Z.), Psychology (R.H.), and Neurosurgery (J.H.Z.), Loma Linda University School of Medicine, School of Science and Technology, Loma Linda, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John H.","family":"Zhang","sequence":"additional","affiliation":[{"name":"From the Departments of Physiology and Pharmacology (W.C., Q.M., H.S., J.T., J.H.Z.), Psychology (R.H.), and Neurosurgery (J.H.Z.), Loma Linda University School of Medicine, School of Science and Technology, Loma Linda, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/1098-2779(200102)7:1<56::AID-MRDD1008>3.0.CO;2-A"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.29.12.2622"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3940(97)13426-7"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.str.0000047101.87575.3c"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/95.1.3"},{"key":"e_1_3_3_7_2","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1111\/j.1349-7006.2008.00911.x","article-title":"Osteopontin promotes ovarian cancer progression and cell survival and increases HIF-1alpha expression through the PI3-K\/Akt pathway","volume":"99","author":"Song G","year":"2008","unstructured":"Song G, Cai QF, Mao YB, Ming YL, Bao SD, Ouyang GL. Osteopontin promotes ovarian cancer progression and cell survival and increases HIF-1alpha expression through the PI3-K\/Akt pathway. Cancer Sci. 2008;99:1901\u20131907.","journal-title":"Cancer Sci"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2010.01524.x"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jcbfm.9600022"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2003.00767.x"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410090206"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2009.06362.x"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0b013e3181c027ae"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-8993(03)02545-9"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1161\/strokeaha.108.531699"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2008.07.003"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.3109\/03008208909002412"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(94)90007-8"},{"key":"e_1_3_3_19_2","first-page":"1967","article-title":"Tissue factor, osteopontin, alphavbeta3 integrin expression in microvasculature of gliomas associated with vascular endothelial growth factor expression","volume":"82","author":"Takano S","year":"2000","unstructured":"Takano S, Tsuboi K, Tomono Y, Mitsui Y, Nose T. Tissue factor, osteopontin, alphavbeta3 integrin expression in microvasculature of gliomas associated with vascular endothelial growth factor expression. Br J Cancer. 2000;82:1967\u20131973.","journal-title":"Br J Cancer"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1161\/strokeaha.108.533109"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410190202"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.8235590"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-009-9356-z"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI12980"}],"container-title":["Stroke"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/STROKEAHA.110.599118","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T14:41:41Z","timestamp":1715611301000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/STROKEAHA.110.599118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["10.1161\/STROKEAHA.110.599118"],"URL":"https:\/\/doi.org\/10.1161\/strokeaha.110.599118","relation":{},"ISSN":["0039-2499","1524-4628"],"issn-type":[{"value":"0039-2499","type":"print"},{"value":"1524-4628","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,3]]},"assertion":[{"value":"2010-08-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2010-11-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2011-01-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}